Skip to main content
. Author manuscript; available in PMC: 2017 Dec 14.
Published in final edited form as: Leuk Res. 2016 Sep 26;50:85–94. doi: 10.1016/j.leukres.2016.09.018

Fig. 4.

Fig. 4

DNA hypermethylation at the region encompassing exon 3 of NR4A3 is associated with its reduced expression in human primary AML samples.

(A) Two human primary AML cell samples were treated with 0.33 μM (AML-1) or 1 μM (AML-2) of DAC for 72 h. The methylation status of CpG sites at the region encompassing exon 3 of NR4A3 in human primary AML samples and control samples (n = 2) was analyzed before and after DAC exposure using bisulfite sequencing. The percentages of methylation at each CpG site are indicated by the black coloring on the pie charts. The percentages of methylation of the total CpG sites in the region of PCR products are also indicated with an average. (B) Two human primary AML cell samples were treated with 0.33 μM (AML-1) or 5 μM (AML-2) of DAC for 72 h. mRNA levels of NR4A3 in primary human cells were evaluated by quantitative real-time PCR and normalized to GAPDH expression. Data are shown as the mean ± S.D. for triplicate analyses. **, P < 0.01, ***, P < 0.001.